Compare CELU & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELU | EVAX |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 33.7M |
| IPO Year | N/A | 2021 |
| Metric | CELU | EVAX |
|---|---|---|
| Price | $1.27 | $3.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $12.33 |
| AVG Volume (30 Days) | 54.7K | ★ 68.2K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,578,000.00 | $7,650,000.00 |
| Revenue This Year | N/A | $128.77 |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 132.17 |
| 52 Week Low | $1.00 | $1.20 |
| 52 Week High | $4.35 | $12.15 |
| Indicator | CELU | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 34.64 |
| Support Level | $1.25 | $3.88 |
| Resistance Level | $1.32 | $4.85 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 34.37 | 8.13 |
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.